AWARD PROGRAM GUIDELINES

AWARD SUMMARY

• The AACR Team Science Award was established by the American Association for Cancer Research and Eli Lilly and Company to acknowledge and catalyze the growing importance of interdisciplinary teams to the understanding of cancer and/or the translation of research discoveries into clinical cancer applications.

• This Award recognizes an outstanding interdisciplinary research team for their innovative and meritorious science that has advanced or may advance our fundamental knowledge of cancer, or a team that has applied existing knowledge to advancing the detection, diagnosis, prevention, or treatment of cancer.

ELIGIBILITY CRITERIA

• Cancer researchers affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science anywhere in the world may be nominated. Such institutions include those in academia, industry, or government.

• Institutions and/or organizations are not eligible to receive the Award.

• Eligible teams may be comprised of independent faculty-level researchers providing complementary interdisciplinary expertise, each of whom have made separate substantive and quantifiable contributions to the research being recognized.

• Team members may be working within the same institution or at several institutions. However, if researchers are employed at the same institution, they must possess separate funding and research space.

• The team research being recognized should reflect work focused on a specific scientific goal that otherwise would not be realized by any single component of the team.

• Teams comprising academic and industry researchers will be accepted.

NOMINATION DEADLINE

• September 30, 2021

NOMINATION PROCESS

• Nominations may be submitted by any individual, whether an AACR member or nonmember, who is currently or has previously been affiliated with any institution involved in cancer research, cancer medicine, or cancer-related biomedical science.

• Self-nominations are prohibited.
• Nominators must maintain strict confidentiality of their nominations and all nominations must be submitted electronically to https://myaacr.aacr.org. Paper nominations will not be accepted.

• Eligible nominations must include the following:
  o A nomination letter written in English (Max: 1,000 words), which comprehensively describes the candidate team’s novel and significant work that has had or may have a far-reaching impact on the etiology, detection, diagnosis, treatment, or prevention of cancer. Letter must specifically outline the team’s current research activity and indicate how their collective research holds promise for continued substantive contributions to the cancer field. All publications that directly support the mentioned research accomplishments must be referenced within the provided letter.
  o A brief scientific citation (Max: 50 words) highlighting the major scientific contribution(s) justifying the team’s nomination.
  o A comprehensive listing of all team members that includes professional title(s), affiliation(s), primary research area(s), and a brief description of each member’s substantive and quantifiable contribution(s) to the team.

AWARD SELECTION
• Eligible nominees will be considered by an Award Selection Committee composed of an international cohort of cancer research experts appointed by the AACR President. After Award Committee deliberations, primary and alternate award recipient recommendations will be relayed to the AACR Executive Committee for formal ratification.

• Selection of the Award recipient shall be made on the basis of the candidate's scientific accomplishments without regard to race, gender, nationality, geographic location, or religious or political views.

INQUIRIES
• Please direct all inquiries pertaining to this Award or any other AACR scientific achievement award or lecture to Michael J. Powell, PhD, Deputy Director of Scientific Programs, at michael.powell@aacr.org or by phone at (215) 440-9373.

PAST AWARD RECIPIENTS
2021 St. Baldrick’s Foundation-Stand Up To Cancer Pediatric Cancer Team
2020 The Cancer Genome Atlas (TCGA) Founders and Current Project Team
2019 St. Jude Cancer Survivorship Research Team
2018 Genomic Approaches to Preventing and Treating Asian-Prevalent Cancers Team
2017 The International Liquid Biopsy Initiative Team
2016 Women’s Health Initiative Team
2015 AR Inhibitor Team
2014 Duke University, Johns Hopkins, and NCI Malignant Brain Tumor Team
2013 Johns Hopkins Cancer Pancreatic Cancer Sequencing Team
2012 The Institute of Cancer Research and Royal Marsden Hospital: Cancer Research UK Cancer Therapeutics Unit & Drug Development Unit Team
2011 Seattle HPV Research Team
2010 Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team
2009 St. Jude Children's Research Hospital Acute Lymphoblastic Leukemia Team
2008 UCSF, Lawrence Berkeley National Laboratory, and Roswell Park Cancer Institute Team
2007 University of Michigan-Brigham and Women's Hospital Team